Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company focused on the discovery, development, and commercialization of proprietary therapeutics. Our first commercial product, JakafiÂŽ (ruxolitinib), is approved in the United States for patients with intermediate or high-risk myelofibrosis and for patients with polycythemia vera who have had an inadequate response to or are intolerant to hydroxyurea. We have a diverse and growing portfolio of product candidates, including both small and large molecules. Source
No articles found.
Jasperate, Inc. is a startup company in the truest sense. We have a strong managem...
Jasperate, Inc. is a startup company in the tru...
Count.It connects with wearable tracking devices and apps to power community fitne...
Count.It connects with wearable tracking device...
Fresenius is a global healthcare group offering high-quality products and services...
Fresenius is a global healthcare group offering...
ZBP is a biopharmaceutical company that has developed a proprietary technology to ...
ZBP is a biopharmaceutical company that has dev...
Recro Pharma (NASDAQ: REPH) is a revenue generating specialty pharmaceutical compa...
Recro Pharma (NASDAQ: REPH) is a revenue genera...
BiondVax is an innovative biopharmaceutical company developing a universal flu vac...
BiondVax is an innovative biopharmaceutical com...
Midatech is an international specialty pharmaceutical company focused on the devel...
Midatech is an international specialty pharmace...
Join the National Investor Network and get the latest information with your interests in mind.